ChangeBridge: Patent Apps - Pharma (A61K)

Kit for Drug-Containing Nanoparticles and Composition for Drug Delivery

The USPTO has published a new patent application (US20260083682A1) by SAMYANG HOLDINGS CORPORATION for a kit and composition for constructing drug-containing nanoparticles for enhanced drug delivery. The application details a method utilizing cationic compounds and anionic polymers to improve cellular drug delivery efficiency.

Protein Nanospheres for Treating Chemotherapy Dysfunction

The USPTO has published a patent application (US20260083683A1) for protein nanospheres designed to treat dysfunction caused by chemotherapy and immunosuppressive therapy. The application details the manufacture and use of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) for mitigating toxic effects of cancer treatments.

Patent Application: Solid Medicinal Forms with Stabilised Active Ingredient

The USPTO has published a new patent application (US20260083677A1) from Astellas Pharma Inc. The application describes solid medicinal forms containing active ingredients stabilized with specific drying agents, aiming for reduced moisture content. This is a new patent filing, not a regulatory rule or guidance.

CRISPR Methods Targeting CD70 Expression for Engineered Cells

The USPTO has published a patent application (US20260083861A1) filed by Editas Medicine, Inc. The application describes CRISPR-related systems and methods for targeting the CD70 gene expression in engineered cells, particularly T cells, for potential therapeutic applications.

Patent Application: Compositions with Sophorolipids and Lactic Acid

The USPTO has published a new patent application (US20260083655A1) filed by Evonik Operations GmbH. The application describes compositions containing sophorolipids and lactic acid for cleaning or skin moisturizing. This is a routine filing for a new patent application.

Patent Application: Tumor Targeting Methods and Reagents

The USPTO has published a patent application (US20260083867A1) detailing methods and reagents for tumor targeting in cancer treatment. The application, filed on November 21, 2025, describes a combination therapeutic approach using agents with different biodistributions to enhance efficacy and reduce toxicity.

USPTO Patent Application for PSMA Ligands

The USPTO has published a new patent application (US20260083865A1) filed by 3B Pharmaceuticals GMBH for prostate specific membrane antigen (PSMA) ligands. The application details a compound of Formula (I) and its use in treating cancer.

Patent Application for Contrast Agents in Diagnostic Imaging

The USPTO has published a patent application (US20260083864A1) for a new class of compounds intended for use as contrast agents in diagnostic imaging, including computed tomography (CT) and magnetic resonance imaging (MRI). The application details specific compound formulas, metal chelates, and preparation methods.

Patent Application: Treating Brain Diseases with rAAV Particles

The USPTO has published a new patent application (US20260083862A1) from the University of Iowa Research Foundation detailing methods for treating brain diseases using rAAV particles administered via the cisterna magna. The application was filed on May 19, 2025.

Patent Application for Genome Editing Compositions and Methods

The USPTO has published a new patent application (US20260083860A1) for genome editing compositions and methods. The application, filed on August 19, 2025, by inventors Oscar ALVAREZ, Ming-Yue LEE, and Blair B. MADISON, details methods and compositions for functional genetic modifications.